ReviewCardiovascular diabetology2023
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction.
Review in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Finerenone Alleviates Cardiac Microvascular Injury and Neutrophil Extracellular Traps Formation in Diabetic Cardiomyopathy via Regulating AKT1 Phosphorylation.Acta physiologica (Oxford, England) · 2026Article
- Finerenone in Heart Failure with Preserved Ejection Fraction: Expanding the Role of Non-steroidal Mineralocorticoid Receptor Antagonists.Current atherosclerosis reports · 2026Review
- Article
- Decoding cardiorenal crosstalk: Intercellular communication mechanisms and therapeutic insights in cardiorenal syndrome.iScience · 2026Review
- Comparative Effectiveness of Finerenone Versus SGLT2 Inhibitors in Patients with HFpEF and CKD: A Real-World Propensity-Matched TriNetX Analysis.Biomedicines · 2026Article
- Review
- Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Comparative effectiveness of finerenone versus steroidal mineralocorticoid receptor antagonists on sepsis-induced cardiomyopathy in patients with diabetic kidney disease: a real-world cohort study.Frontiers in pharmacology · 2026Article
- A Review on Finerenone and Heart Failure with Preserved Ejection Fraction (HFpEF).Cardiovascular & hematological disorders drug targets · 2026Review
- Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines.Biomolecules · 2025Article
- The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy.Medicina (Kaunas, Lithuania) · 2025Review
- Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Finerenone and semaglutide: Role in heart failure with reduced ejection fraction.World journal of cardiology · 2025Article
- The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?Cardiovascular diabetology · 2025Review
- Cardiorenal Syndrome in Heart Failure with Preserved Ejection Fraction: Insights into Pathophysiology and Recent Advances.Cardiorenal medicine · 2025Review
- Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects.Heart failure reviews · 2025Review
- Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders.Pharmacological reports : PR · 2024Review
- Glomerular pressure and tubular oxygen supply: a critical dual target for renal protection.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms.Diabetology & metabolic syndrome · 2024Review
- Proximal versus distal diuretics in congestive heart failure.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with high binding affinity, high MR selectivity and a short plasma half-life. In two major endpoint-driven clinical trials in patients with chronic kidney disease and type 2 diabetes mellitus (FIDELIO-DKD and FIGARO-DKD), finerenone induced significant cardiorenal protective actions, and has been recently approved for treatment of these patients. Heart failure with preserved ejection fraction (HFpEF) is a devastating clinical syndrome with increasing prevalence and poor prognosis. Pharmacological therapy of HFpEF is very limited and new therapeutic options are urgently needed. Finerenone has been shown to improve multiple pathophysiological parameters of HFpEF in preclinical models. In consonance, pre-specified subgroup analyses of FIDELIO-DKD and FIGARO-DKD suggested a potential beneficial effect of finerenone in HFpEF. This review will discuss the pharmacodynamic and -kinetic profile of finerenone. We will provide a general overview over the complex pathophysiology of HFpEF and data from pre-clinical studies, focusing on how finerenone improves multiple components of this pathophysiology. Finally, we will discuss current and future clinical trials with finerenone in heart failure patients focusing on HFpEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.